Bristol-Myers Squibb 2026 Clinical Milestones and Guidance Outlook

Key 2026 clinical milestones at Bristol Myers Squibb (BMS) that could influence guidance

BMS repeatedly frames late-2026 readouts as central to derisking its long-term growth profile—i.e., the outcomes that can materially affect confidence in future revenue and, by extension, how management feels about full-year or forward guidance updates during 2026. ¹

1) Milvexian pivotal readouts in thrombosis (AFib and Secondary Stroke Prevention)

• BMS expects Factor XI inhibitor milvexian trials in atrial fibrillation (AFib) and secondary stroke prevention (SSP) to have readouts by the end of 2026. ²³
• Management emphasizes that in AFib, the study design includes non-inferiority vs apixaban followed by superiority testing for bleeding outcomes, and they state they are on track with both endpoints. ³
• These milestones matter for guidance because BMS ties them to the goal of maintaining leadership in the thrombotic space (“BMS will be the only Factor XI company…”) and to “confidence remains absolutely unchanged” for milvexian. ²

Why it could influence guidance: Successful pivotal readouts (especially those demonstrating the intended non-inferiority and bleeding profile advantages) would strengthen the case for near- to mid-term portfolio expansion and could support higher confidence in growth assumptions used in guidance updates. ²³

---

2) Cobenfy (Alzheimer’s disease/psychosis) readouts and trial progress through 2026

BMS highlights multiple aspects of Cobenfy clinical execution and notes “a very data rich 2026 and even probably more ’27.” ²

Key 2026 milestones referenced in the excerpts:

• BMS calls Cobenfy “a critical readout this year” in the context of Alzheimer’s psychosis. ⁴
• In addition to schizophrenia, management discusses prior schizophrenia data and open-label evidence in Adept 1 as rationale for confidence in expanding use to psychosis-related settings. ⁴
• BMS states that Cobenfy study designs and trial conduction are under control. ⁴

Why it could influence guidance: Cobenfy contributes to the company’s growth narrative, and late-2026/near-late-2026 pivotal readouts that validate efficacy/safety profiles in Alzheimer’s psychosis could change expectations for the size/timing of revenue ramp and pipeline value—factors that management typically considers in guidance confidence. ⁴²

---

3) Iberdomide/related CELMoD pivotal/regulatory timing in multiple myeloma (PFS readout and FDA process)

BMS references CELMoD milestones as part of its 2026 clinical cadence:

• BMS says it achieved positive MRD with iberdomide (in multiple myeloma context) and expects PFS later in 2026. ²
• It also notes an FDA acceptance of an iberdomide filing with breakthrough therapy designation and priority review, with a PDUFA date of August 17. ⁵
• The excerpt also mentions that management expects PFS data and provides an explicit comment that the PFS is later this year. ²

Why it could influence guidance: In oncology/CELMoD, a pivotal PFS readout and/or regulatory progress (priority review/breakthrough designations) can materially affect market expectations for launch timing, uptake, and durability—inputs that commonly shape how management supports or adjusts guidance. ²⁵

---

4) Neuroscience program readouts (ADP studies in Cobenfy) by end of 2026

• BMS expects ADP studies (denoted as “ADP…2 and 4”) to have readouts by the end of 2026. ²
• Management explicitly states this timing is based on managing studies “with the same time lines” and that they “need the 2 studies probably for an approval.” ²

Why it could influence guidance: Approval-oriented readouts by year-end can sharpen confidence around regulatory success and commercial trajectory, which can in turn affect management’s confidence in growth projections used in guidance updates. ²

---

5) Admilparant (immunology) pivotal guidance points: IPF/PF(P) outcomes timing

BMS calls admilparant a “critical readout this year” spanning immunology and IPF/PPF:

• It is described as a first-in-class inhibitor with “a very differentiated profile… on efficacy side but also on the safety side.” ⁴
• BMS says IPPF is guided by the end of the year and PPF is a few months later, probably beginning ’27. ⁴

Why it could influence guidance: Differentiated efficacy/safety readouts in difficult-to-treat diseases (and those near year-end) can expand the risk-adjusted view of the pipeline’s revenue contribution—especially because BMS is emphasizing an increasing cadence of “pivotal readouts” expected later in 2026. ⁴¹

---

Net impact: the “end-of-2026 pivotal readout cadence” management highlights

Management explicitly frames the latter part of 2026 as “shaping up” to include an increasing cadence of pivotal readouts expected to “define and derisk” long-term growth. ¹ In the excerpt, the Phase III readouts it lists for late 2026/around that time include:

• Milvexian in AFib and secondary stroke prevention ¹
• Cobenfy in Alzheimer’s psychosis ¹
• Iberdomide PFS data (multiple myeloma) ¹

Separately, BMS reaffirms guidance for the full year 2026:

• BMS says it is reaffirming financial guidance for the full year of 2026, and that performance is tracking toward the upper end of established revenue and EPS guidance. ⁶

How the milestones matter for guidance specifically: the end-of-year pivotal readouts BMS highlighted are the clinical events that are most likely to cause management to adjust forward confidence (and potentially subsequent guidance updates) because they can change perceived probability-weighted value of future product lines—yet, at the time of the excerpt, BMS states guidance is reaffirmed. ¹⁶

---